Medical therapy for obesity: Present and future

Israel Medical Association Journal

Volumn 6, Issue 12, 2004, Pages 760-765

  Ness Abramof, Rosane ^a,c   Nabriski, Dan ^a,c   Apovian, Caroline M ^b,d  

^a MEIR MEDICAL CENTER   (Israel)

^b BOSTON MEDICAL CENTER   (United States)

^c TEL AVIV UNIVERSITY   (Israel)

^d BOSTON UNIVERSITY   (United States)

Author keywords

Cardiovascular disease; Co morbidity; Diabetes; Obesity; Pharmacotherpay; Stroke

Indexed keywords

AMFEBUTAMONE; ANTIOBESITY AGENT; BETA 3 ADRENERGIC RECEPTOR STIMULATING AGENT; CHOLECYSTOKININ RECEPTOR STIMULATING AGENT; CILIARY NEUROTROPHIC FACTOR; FENFLURAMINE; GHRELIN; GLUCAGON LIKE PEPTIDE 1; LEPTIN; METFORMIN; PEPTIDE YY; PHENTERMINE; RIMONABANT; SIBUTRAMINE; TETRAHYDROLIPSTATIN; TOPIRAMATE; UNCLASSIFIED DRUG;

BEHAVIOR THERAPY; BODY MASS; BODY WEIGHT; CALORIC INTAKE; CANCER RISK; CLINICAL TRIAL; COMORBIDITY; CONSTIPATION; COUGHING; DIABETES MELLITUS; DISEASE EXACERBATION; DOSE RESPONSE; DRUG ABSORPTION; DRUG MECHANISM; DRUG METABOLISM; DYSLIPIDEMIA; ENERGY EXPENDITURE; EXERCISE; GASTROINTESTINAL DISEASE; GASTROINTESTINAL SYMPTOM; HEART PALPITATION; HUMAN; HYPERTENSION; INJECTION PAIN; INJECTION SITE; INSOMNIA; ISCHEMIC HEART DISEASE; LOW CALORY DIET; METABOLIC DISORDER; MYALGIA; NAUSEA; OBESITY; PHYSICAL ACTIVITY; PULSE RATE; REVIEW; SIDE EFFECT; SLEEP APNEA SYNDROME; STEATORRHEA; STROKE; WEIGHT REDUCTION; XEROSTOMIA;

ANTI-OBESITY AGENTS; APPETITE DEPRESSANTS; BEHAVIOR THERAPY; BODY MASS INDEX; DIABETES MELLITUS, TYPE 2; EXERCISE; FEMALE; FOOD HABITS; FORECASTING; GASTROINTESTINAL DISEASES; HUMANS; HYPERTENSION; MALE; METABOLIC SYNDROME X; NEOPLASMS; OBESITY; RISK FACTORS;

EID: 10644249061     PISSN: 15651088     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (40)

1. Must A, Spadano J, Coakley E, Field AG, Colditz G, Dietz WH. The disease burden associated with overweight and obesity. JAMA 1999; 282:1523-9.
2. Rosenbaum M, Leibel RL, Hirsch J. Obesity. N Engl J Med 1997;337:396-407.
3. Clinical Guidelines on the identification, evaluation and treatment of overweight and obesity in adults: the evidence report. Obes Res 2001;6:S51-209.
4. Despres JP. The insulin resistance-dyslipidemic syndrome of visceral adiposity: effect on patients' risk. Obes Res 2001;6:8-17S.
5. Rosenbaum M, Leibel R. The role of leptin in human physiology. N Engl J Med 1999;341:913-15.
6. Considine RV, Sinha MK, Heimman ML, et al. Serum immunoreactive-leptin concentration in normal weight and obese humans. N Engl J Med 1996;334:292-5.
7. Nakazato M, Murkami N, Date Y, et al. A role of ghrelin in the central regulation of feeding. Nature 2001;409:194-8.
8. Batterham RL, Cohen MA, Ellis SM, et al. Inhibition of food intake in obese subjects by peptide YY. N Engl J Med 2003 349:941-8.
9. Yanovski SZ, Yanovski JA. Obesity. N Engl J Med 2002;346:591-602.
10. Leibel RL, Rosenbaum M, Hirsch J. Changes in energy expenditure resulting from altered body weight. N Engl J Med 1995;332:621-8.
11. Harris ML, Flegal KM, Cowie CC, et al. Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in US adults: the Third National Health and Nutrition Examination Survey. Diabetes Care 1998;21:518-24.
12. Colditz GA, Willet WC, Ronitzky A, Manson JE. Weight gain as a risk factor for clinical diabetes mellitus in women. Ann Intern Med 1995;122:481-6.
13. Diabetes Prevention Program Research Group. Reduction in the Incidence of type 2 diabetes with lifestyle intervention or Metformin. N Engl J Med 2002;346:393-403.
14. Hall JE, Hildenbrandt DA, Kuo J. Obesity hypertension. Role of leptin and sympathetic nervous system. Am J Hypertens 2001;14:103-15S.
15. Manson JE, Colditz GA, Stampfer MJ, et al. A prospective study of obesity and risk of coronary heart disease in women. N Engl J Med 1990;322:882-9.
16. Kenchaiah S, Evans JC, Levy D, et al. Obesity and risk of heart failure. N Engl J Med 2002;347:305-13.
17. Garrison RJ, Kannel WB. A new approach for estimating healthy body weights. Int J Obes Relat Metab Disord 1993;17:417-23.
18. DeFronzo RA, Ferranini E. Insulin resistance: a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia and atherosclerotic vascular disease. Diabetes Care 1991;14:173-94.
19. Executive Summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection. Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486-97.
20. Everhart JE. Contributions of obesity and weight loss to gallstone disease. Ann Intern Med 1993;119:1029-35.
21. Angulo P. Non alcoholic fatty liver disease. N Engl J Med 2002;346:1221-31.
22. National Task Force on Prevention and Treatment of Obesity: overweight, obesity and health risk. Arch Intern Med 2000;160:898-904.
23. Huang Z, Hankinson SE, Colditz GA, et al. Dual effects of weight and weight gain on breast cancer risk. JAMA 1997;278:1407-11.
24. Calle EE, Rodriguez C, Walker-Thurmond BA, Thun J. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of US adults. N Engl J M 2003;348:1625-38.
25. The Practical Guide to Identification, Evaluation and Treatment of Overweight and Obesity in Adults. Bethesda, MD: National Institutes of Health, 2002, publication # 00-4084.
26. Wadden TA, Foster GD, Letizia KA. One-year behavioral treatment of obesity: comparison of moderate and severe caloric restriction and the effects of weight maintenance therapy. J Consult Clin Psychol 1994;62:165-71.
27. Wing RR, Hill JO. Successful weight loss maintenance. Annu Rev Nutr 2001;21:323-41.
28. Wing RR, Goldstein MG, Acton K, et al. Behavioral science research in diabetes: lifestyle changes related to obesity, eating behavior, and physical activity. Diabetes Care 2001;241:117-23.
29. Lichtman SW, Pisarska K, Berman ER, et al. Discrepancy between self-reported and actual caloric intake and exercise in obese subjects. N Engl J Med 1992;327:1893-8.
30. Weintraub M, Sundaresan PR, Schuster B, et al. Long-term weight control study IV (weeks 150-190). The second double blind phase. Clin Pharmacol 1992;51:608-14.
31. Langlois KJ, Forbes JA, Bell GW, et al. A double-blind clinical evaluation of the safety and efficacy of phentermine hydrochloride (Fastin) in the treatment of exogenous obesity. Curr Ther Res Clin Exp 1974;16:289-96.
32. James WPT, Astrup A, Finer N, et al. Effect of sibutramine on weight maintenance after weight loss: a randomized trial. Lancet 2000;356:2119-22.
33. Rolls BJ, Shide DJ, Thorwart ML, Ulbrecht JS. Sibutramine reduces food intake in non-dieting women with obesity. Obes Res 1998;6:1-11.
34. Bray GA, Blackburn GL, Ferguson J, et al. Sibutramine produces dose-related weight loss. Obes Res 1999;7:189-98.
35. Thearle M, Aronne LJ. Obesity and pharmacologic therapy. Endocrinol Metab Clin North Am 2003;32:1005-24.
36. Apfelbaum M, Vague P, Ziegler O, Hanoi C, Thomas F, Leutenegger E. Long-term maintenance of weight loss after a very-low-calorie diet. A randomized blended trial of the efficacy and tolerability of sibutramine. Am J Med 1999;106:179-84.
37. Hauptman J, Lucas C, Boldrin MN, Collins H, Segal KR. Orlistat in the long-term treatment of obesity in primary care settings. Med Arch Fam 2000;9:160-7.
38. Torgerson JS, Boldrin MN, Hauptman J, Sjostrom L. XENical in the prevention of Diabetes in Obese Subjects (XENDOS) study. Diabetes Care 2004;27:155-61.
39. Sjostrom L, Risganen A, Andersen T, et al. Randomized placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicenter Orlistat Study Group. Lancet 1998;352:167-72.
40. Madsbad S, Schmitz O, Ranstam J, Jakobsen G, Matthews DR. Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting Glucagon-like peptide 1 analog Liraglutide (NN2211). Diabetes Care 2004;27:1335-42.